Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway
Xinglong Ma, Wenyuan Xu, Xinmeng Jin, Haoran Mu, Zhuoying Wang, Yingqi Hua, Zhengdong Cai, Tao Zhang
Journal:EUROPEAN JOURNAL OF PHARMACOLOGY
IF:5
DOI:10.1016/j.ejphar.2023.175529
PMID:36690054
Published:2023-01-20
research field:神经科学分子生物学脑卒中治疗中医中药民族药理学
Abstract
Osteosarcoma is the most common primary bone malignancy in children and adolescents; it exhibits rapid growth and a high metastatic potential and may thus lead to relatively high mortality. The JAK2/STAT3 signaling pathway, which plays a critical role in the occurrence and development of osteosarcoma, is a potential target for the treatment of osteosarcoma. Here, we identified the natural product telocinobufagin (TCB), which is a component isolated from toad cake, as a potent candidate with anti-osteosarcoma effects. TCB inhibited osteosarcoma cell growth, migration, invasion and induced cancer cell apoptosis . Mechanistically, TCB specifically inhibited the JAK2/STAT3 signaling pathway. More importantly, TCB significantly suppressed tumor growth and metastasis in an osteosarcoma xenograft animal model. Moreover, TCB also showed strong inhibitory effects in other cancer types, such as lung cancer, liver cancer, colon cancer , breast cancer and gastric cancer. Hence, our study reveals TCB as a potent anti-osteosarcoma therapeutic agent that inhibits the JAK2/STAT3 signaling pathway.
本文使用的Yeasen产品


